Advertisement

Topics

Companies Related to "Study of Vinblastine and Sirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors Including Central Nervous System Tumors" [Most Relevant Company Matches] RSS

00:58 EDT 17th October 2018 | BioPortfolio

Here are the most relevant search results for "Study of Vinblastine and Sirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors Including Central Nervous System Tumors" found in our extensive corporate database of over 50,000 company records.

Showing "Study Vinblastine Sirolimus Pediatric Patients With Recurrent Refractory" Companies 1–25 of 4,300+

Relevant

DACOGEN

DACOGEN is indicated for treatment of patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS of all French-American-British (FAB) subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia) and i...


bluebird bio, Inc. bluebird bio to Present Updated Clinical Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti- BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASCO Annual Meeting

Florida Hospital for Children

The Walt Disney Pavilion at Florida Hospital for Children is a full-service facility served by more than 70 pediatric specialists, one of the largest panels of pediatric experts in Central Florida and a highly trained pediatric team of more than 600 employees. This unique children's hospital provides patients with private, family-centered pediatric rooms, a dedicated pediatric emergency department...


Verastem Oncology

Verastem, Inc. (Nasdaq:VSTM), operating as Verastem Oncology, is a biopharmaceutical company focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients. Verastem Oncology is currently developing duvelisib, a dual inhibitor of PI3K-delta and PI3K-gamma, which has successfully met its primary endpoint i...

BioClin Therapeutics, Inc.

BioClin Therapeutics, Inc. is a privately-held clinical stage drug development company developing biologics to address medical conditions in areas of high unmet need. The company’s lead candidate is B-701, a potential first-in-class human monoclonal antibody targeting FGFR3 (fibroblast growth factor receptor 3). B-701 is currently being evaluated in t...

ACRO

Health outcomes aren't jeopardized when patients participate in randomized clinical trials of approved treatments, according to a new study. The results address misgivings some physicians have had about whether enrolling patients in a clinical trial might have a detrimental impact on their ability to receive individualized treatment. Conducted by a team led by Yale University's Dr. Cary P. Gross, ...

The Heart Institute For Children

THIC was founded in 1987 by a group of Pediatric Cardiologists from the University of Chicago, NorthWestern University (Children's Memorial Hospital) and Loyola University. These physicians, all of whom had professional appointments at their respective institutions, felt that they could provide optimal care for their pediatric patients in a differently structured environment. They located THIC at ...

TxCell

TxCell, a spin-off of Inserm (France’s National Institute for Health and Medical Research) is located in the Sophia Antipolis technology park, Nice, France. It is developing innovative personalized cell-based immunotherapies for the treatment of severe chronic inflammatory diseases with high medical need using its unique and proprietary technology platform based on the properties of autolo...

Pediatric Cancer Research Foundation

The Pediatric Cancer Research Foundation (PCRF) is an independent, nonprofit organization, wholly dedicated to funding leading-edge pediatric cancer research nationwide. Since its founding in 1982, PCRF has raised over $30 million dollars towards the ultimate goal of ending pediatric cancers so children and their families can re-focus on the joys of childh...

Erimos Technologies, LLC

Erimos has exclusive license for nordihydroguaiaretic acid (NDGA) derivatives from The Johns Hopkins University. We have developed a novel process to extract NDGA from the resin of the leaves of Larrea tridentata, a desert plant indigenous to the southwestern US and Mexico. EM-1421, our lead candidate, is a semi-synthetic derivative of NDGA. It is designed to target specific differences between no...

Longboat Clinical

Longboat is a clinical trials software company dedicated to generating better study outcomes by creating a complete support structure for site staff, patients, monitors, and study teams - where protocol compliance becomes easy and instinctive. In the complex world of clinical development, Longboat’s cloud-based site and patient engagement platform emp...

GlobalCare Clinical Trials, Ltd

GlobalCare Clinical Trials, Ltd, is the leading global provider of ambulant healthcare services for clinical trials to government agencies and the world’s biopharmaceutical and medical device companies engaged in all phases of product development. GlobalCare provides innovative, GCP-compliant services by conducting selected study visits in the home or...

NPS Pharmaceuticals, Inc.

NPS Pharmaceuticals is developing new treatment options for patients with rare gastrointestinal and endocrine disorders. The company is currently advancing two Phase 3 registration programs. Teduglutide, a proprietary analog of GLP-2, is being evaluated as GATTEX® in a Phase 3 registration study known as STEPS for intestinal failure associated with shor...

Santalis Pharmaceuticals, Inc.

Santalis Pharmaceuticals, Inc. is a wholly-owned subsidiary of TFS Corporation, Ltd. (ASX: TFC). Santalis, and its sister company, ViroXis, were acquired by TFS in July 2015 and are developing scientifically and clinically validated over the counter and prescription products that utilize TFS’ cultivated, sustainable, pharmaceutical-grade East Indian S...

Genetronics Biomedical

Genetronics' most advanced effort involves treating those with head and neck cancer, a particularly devastating cancer that can severely limit the ability of these patients to see, taste, hear, talk, breathe, or swallow. Genetronics received approval from the U.S. Food and Drug Administration and initiated Phase II multi-center clinical trials at nine sites in the U.S. The trials test the effectiv...

The Finnish Breast Cancer Group

The study, led by the Finnish Breast Cancer Group, was a large open-label, two-arm, randomised multicentre phase III study in women with early breast cancer. 1,500 patients in Finland and Sweden with no distant metastases who had an intermediate to high risk of recurrence within five years from the time of diagnosis, were recruited to the study.

FSC Therapeutics, LLC

FSC Pediatrics, Inc., a subsidiary of FSC Laboratories, based in Charlotte, NC, is a specialty pharmaceutical and medical device company founded in 2004, solely dedicated to providing innovative solutions to unmet medical needs for pediatric patients. FSC Pediatrics provides products that meet pediatric primary care and specialist needs in the following th...

Pharmacon Research GmbH

Pharmacon Research is an independent contract research organization (CRO) with headquarters in Berlin and clinical sites in Prague, Warsaw, Bratislava and Budapest. Founded in 1992 by the management of a successful Phase I unit, Pharmacon Research focuses on specific Phase I studies in patients and symptomatic subjects and on early Phase II studies (dose finding, proof of concept). Irrespective of...

Aranesp

Aranesp® (darbepoetin alfa) is indicated for the treatment of anemia associated with chronic renal failure (CRF), including patients on dialysis and patients not on dialysis, and for the treatment of anemia in patients with nonmyeloid malignancies where anemia is due to the effect of concomitantly administered chemotherapy.Important Product Safety InformationAranesp® is contraindicated in patien...

Eisner Pediatric & Family Medical Center

For 95 years, Eisner Pediatric & Family Medical Center has been a premier deliverer of high-quality health care and social services for low and moderate-income residents, underserved communities, and vulnerable populations in Los Angeles County. Eisner provides primary medical, dental and mental healthcare, and its programs and services include women’...

Cardiac Surgical Associates

Cardiac Surgiacal Associates is an association of twenty board-certified physicians specializing in the care of pediatric and Adult patients with cardiac, Thoracic,and Vascular disease. They are the largest combined adult anf pediatric practice in Florida prociding cardiovascular and thoracic surgery and cardiac transplantation. They work as a team to provide the highest quality medical care avail...

Imposter Research

IMPOSTER is the name of a medical research study of patients with muscle symptoms while taking cholesterol lowering therapies called statins. Several important findings from this study have been published and have raised questions about the safety of statin therapy for patients with muscle complaints. This website was developed to address those questions and to share what is known about statin mu...

Shape Pharmaceuticals, Inc.

Shape Pharmaceuticals, Inc. is developing SHP-141, a novel, topical, “soft-drug” HDAC inhibitor for the treatment of patients with cutaneous T cell lymphoma (CTCL) and psoriasis. Shape has an ongoing Phase 1b clinical study in CTCL patients and has completed a Phase 1b clinical study in psoriasis patients. The development of SHP-141 is being supp...

Columbia Eastside

The Columbia Eastside facility, located at 16 East 60th Street, between Madison and Fifth Avenues houses a clinical practice of over 200 physicians representing 128 specialties and subspecialties. The Fetal Cardiology Program at the Morgan Stanley Children's Hospital of New York-Presbyterian Hospital - Columbia Eastside is a component of the Center for Prenatal Pediatrics, a joint venture of the D...

Canines-N-Kids Foundation

WHATCanines-N-Kids Foundation, a nonprofit committed to finding a cure to the devastating cancers that canines and children both develop, is hosting the first Paws for a Cure Summit. With a significant grant from the Petco Foundation in conjunction with the Blue Buffalo Foundation, the event is convening the foremost leaders and researchers i...


More From BioPortfolio on "Study of Vinblastine and Sirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors Including Central Nervous System Tumors"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks